R&D

UniQuest and the Ellison Medical Institute have signed an exclusive licence that could push a promising University of Queensland treatment for advanced prostate cancer into first-in-human trials as early as 2027.

Tetratherix has announced that its joint venture, Tutelix, has received approval from the Human Research Ethics Committee in Australia to start an international pivotal clinical trial for its hydrogel spacer.

Invion has taken a step to strengthen its clinical leadership by appointing Dr Colin Hopper, a globally recognised authority in photodynamic therapy, as a clinical advisor.

Recce Pharmaceuticals has received approval from the Human Research Ethics Committee to advance its Australian study of RECCE 327 Topical Gel to a pivotal Phase 3 trial for diabetic foot infections, a move the company says accelerates its global registration strategy.

MTPConnect has adopted a new name as it enters its second decade, rebranding itself as AUScelerate. The organisation said the change aims to better reflect its mission to commercialise Australian life sciences.

Dr Christian Toouli, CEO and Managing Director of FivepHusion, said, "The ethics approval of the Phase II DART protocol is an exciting milestone towards our goal of evaluating Deflexifol as a promising therapy for these patients."

AusBiotech has announced that Australia's Biggest Week in Biotech 2027 will be held in Brisbane from 23–27 August, marking a shift from its traditional October timing.

Atmo Biosciences has been named a winner in Fast Company’s 2026 World Changing Ideas Awards, an annual program that recognises innovations delivering measurable impact across industries.

Dr Chris Baldwin, CEO and Managing Director, said, “Receipt of ethics approval for our KappaMab Phase 2b clinical trial in combination with pomalidomide and dexamethasone is a significant milestone for HaemaLogiX."

Neurizon Therapeutics has executed a long-term supply agreement with Elanco Animal Health that gives the company access to scalable Good Manufacturing Practice supply of monepantel, the active pharmaceutical ingredient in its lead asset NUZ‑001.

Percheron Therapeutics has announced the successful completion of manufacturing for a new batch of HMBD-002 drug substance ahead of planned clinical trials.

Racura Oncology has secured $34.3 million following a series of fundraising initiatives supported by new and existing shareholders, giving the company a strong cash balance to fully fund its RC220 clinical programs in Acute Myeloid Leukaemia, EGFRm non-small cell lung cancer and anthracycline cardioprotection in solid tumour patients.